21 – 30 of 88
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images
(
- Contribution to journal › Article
-
Mark
Impact of the COVID-19 pandemic on nuclear medicine departments in Europe
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
(
- Contribution to journal › Article
-
Mark
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia
(
- Contribution to journal › Article
-
Mark
Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts
(
- Contribution to journal › Article
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
(
- Contribution to journal › Scientific review
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948
(
- Contribution to journal › Article
-
Mark
Letter to editor
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Regional [18F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
(
- Contribution to journal › Article